Table 1 Clinicopathological features of HBV patients in Study 1.

From: Circulating thrombospondin 2 as a predictor of hepatocellular carcinoma in hepatitis B patients undergoing nucleos(t)ide analog therapy

 

All (n = 87)

Median (IQR)

Age, years

48 (35–57)

Male, n (%)

51 (58.6%)

PLT, × 104/µL

15.7 (11.8–20.8)

Alb, g/dL

4.2 (4.0–4.5)

T. Bil, mg/dL

0.83 (0.65–1.05)

AST, U/L

52 (33–112)

ALT, U/L

73 (39–205)

TSP2, ng/mL

21.0 (14.2–31.4)

M2BPGi, C.O.I

1.00 (0.62–2.05)

HBeAg ( +), n (%)

50 (57.5%)

HBV-DNA, log IU/mL

6.1 (4.9–7.8)

Fibrosis stage (F0-1/F2/F3/F4)

31/22/15/19

Activity stage (A0/A1/A2/A3)

4/24/42/17

  1. Alb, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; IQR, interquartile range; M2BPGi, mac-2 binding protein glycan isomer; PLT, platelet count; T. Bil, total bilirubin; TSP2, thrombospondin 2.
Back to article page